| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10548875 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10052267 | JOURNEY | Topical glycopyrrolate formulations |
Oct, 2028
(5 years from now) | |
| US8618160 | JOURNEY | Topical glycopyrrolate formulations |
Dec, 2029
(6 years from now) | |
| US9744105 | JOURNEY | Topical glycopyrrolate formulations |
Jul, 2030
(6 years from now) | |
| US10004717 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(9 years from now) | |
| US10543192 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(9 years from now) | |
| US8859610 | JOURNEY | Crystalline glycopyrrolate tosylate |
Feb, 2033
(9 years from now) | |
| US9259414 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(9 years from now) | |
Qbrexza is owned by Journey.
Qbrexza contains Glycopyrronium Tosylate.
Qbrexza has a total of 8 drug patents out of which 0 drug patents have expired.
Qbrexza was authorised for market use on 28 June, 2018.
Qbrexza is available in cloth;topical dosage forms.
Qbrexza can be used as topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.
The generics of Qbrexza are possible to be released after 28 February, 2033.
Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient
Market Authorisation Date: 28 June, 2018
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: CLOTH;TOPICAL
QBREXZA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic